{"disease":{"id":"desmoid-tumors","name":"desmoid tumors"},"drugs":{"marketed":[{"drug_id":"nirogacestat","indication_name":"progressing desmoid tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ogsiveo","generic_name":"NIROGACESTAT","company_name":"Springworks","drug_phase":"marketed","molecular_target":"","drug_class":"Gamma Secretase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"Nirogacestat works by blocking the gamma secretase enzyme, which is involved in the development and progression of desmoid tumors."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01981551","title":"Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05111964","title":"HIFU Ablation of Soft Tissue Sarcoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Oxford University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT05041036","title":"Individual Patient Compassionate Use of Nirogacestat","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"SpringWorks Therapeutics, Inc.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}